XBiotech Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
XBiotech Inc. is a biotechnology company whose core business model is the development of monoclonal antibody therapeutics. This research and development process inherently involves animal testing as a standard, required component of preclinical safety and efficacy studies to gain regulatory approval for human trials. The company’s lead investigational asset, bermekimab, was advanced through such studies prior to its acquisition by Janssen Biotech.
Cruelty Free Investors, an organization screening for animal exploitation in corporate activities, flags XBiotech in its “Companies That Exploit Animals” database under the category “Animal Testing.” This indicates the company’s business is materially reliant on animal-based research methodologies. For a biotechnology firm focused on novel antibody therapies, animal models are a central, non-optional element of the product development pathway, constituting commercial exploitation of animals under the fund’s criteria.
XBiotech Inc. is a pre-market biopharmaceutical company engaged in discovering and developing monoclonal antibody therapeutics for inflammatory diseases and cancer. The company’s Form S-1 registration statement notes that its development process “generally begins with laboratory testing and experiments,” which for antibody drug candidates typically includes in vivo animal testing to establish safety and efficacy prior to human clinical trials. Published research on its therapeutic targets, such as IL-1β, cites animal experiments as foundational to the scientific understanding it seeks to commercialize.
As a clinical-stage biotechnology firm, XBiotech’s core business model is predicated on the research and development of novel biologic drugs. This process inherently requires animal testing to meet regulatory requirements for investigational new drug applications with agencies like the U.S. Food and Drug Administration. The company’s pipeline and research funding, as noted in scientific literature, are directly tied to this preclinical development pathway.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.